Adage Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-553,000
Closed -$3.77M – 1145
2026
Q2
$3.77M Buy
+553,000
New +$3.27M 0.01% 835
2026
Q1
– Sell
-1,328,000
Closed -$7.3M – 1076
2025
Q4
$7.3M Sell
1,328,000
-2,000,000
-60% -$9.7M 0.01% 718
2025
Q3
$10.9M Sell
3,328,000
-1,511,000
-31% -$4.28M 0.02% 611
2025
Q2
$11.2M Buy
+4,839,000
New +$10.5M 0.02% 592
2025
Q1
– Sell
-5,000,000
Closed -$8.65M – 945
2024
Q4
$8.65M Buy
+5,000,000
New +$10.4M 0.02% 642
2024
Q2
– Sell
-220,000
Closed -$631K – 939
2024
Q1
$631K Sell
220,000
-200,000
-48% -$417K ﹤0.01% 803
2023
Q4
$743K Sell
420,000
-1,080,000
-72% -$2.15M ﹤0.01% 771
2023
Q3
$4.74M Buy
+1,500,000
New +$2.8M 0.01% 670

Other funds holding TSHA

Adage Capital Partners's TSHA Position: Q3 2026 in Review

Adage Capital Partners sold out of Taysha Gene Therapies (TSHA) in Q3 2026, closing a stake of 553,000 shares — an estimated $3.77M sold.

Adage Capital Partners first reported a position in TSHA in Q3 2023 and held it in 8 quarters. The position peaked at $11.2M in Q2 2025. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Adage Capital Partners reported no remaining Taysha Gene Therapies position as of Q3 2026 after selling out during the quarter.
  • Adage Capital Partners sold 553,000 Taysha Gene Therapies shares in Q3 2026, an estimated $3.77M.
  • Adage Capital Partners first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 8 quarters.
  • Adage Capital Partners's Taysha Gene Therapies position peaked at $11.2M in Q2 2025.
  • 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.